New study finds potential link between GLP1 agonists and depression, urging further investigation into patient safety.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Eli Lilly and Company has announced positive topline Phase 3 results from Achieve-1, evaluating the safety and efficacy of ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...